Alkihiro Yoshida

5PUBLICATIONS
9CO-AUTHORS
PharmacogenomicsMolecular targetsElectrochemical energy storage and conversionMedical biochemistry - carbohydrates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 26, 2021
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.

Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami

|Feb 26, 2020
Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance.

T Nojima, Y Matsubayashi, A Yoshida

|Jan 28, 2020
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.

Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami

|Oct 15, 2019
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.

Yuichi Sato, Kiyohide Nunoi, Kohei Kaku

Pageof 1

Frequent Collaborators

4 joint publications

Kohei Kaku

4 joint publications

Hideki Suganami

2 joint publications

Hirohito Sone

2 joint publications

Yasuhiro Matsubayashi